Study reveals artery stiffness from common cancer drug

NCT ID NCT04813913

Completed Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how bevacizumab, a drug used to treat advanced colorectal cancer, affects the stiffness of arteries. Researchers measured artery stiffness in 13 patients before and after 4 months of treatment. The goal was to better understand the drug's cardiovascular side effects, like high blood pressure, and how they relate to cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin) combined with chemotherapy
What this could lead to: If successful, this could help doctors understand and manage the cardiovascular side effects of bevacizumab in colorectal cancer patients.
What could go wrong: This is a small, completed Phase 4 study with only 13 participants, so results may not apply broadly. It focuses on measuring artery stiffness, not on improving cancer outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ONCOLOGY

Contacts and locations

Locations

CHU de ROUEN

Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.